PolarityBio Development Pipeline

PolarityBio’s pipeline reflects a disciplined focus on developing investigational regenerative biologics for chronic wound healing. The lead program, SkinTE®, is an autologous multicellular skin therapy that has recently completed a Phase III pivotal clinical trial for Wagner Grade 1 diabetic foot ulcers. Additional pipeline programs leverage the same regenerative biology platform to address other high-unmet-need indications.

SkinTE® Regenerative Biologics Platform Pipeline

PolarityBio pipeline showing SkinTE investigational regenerative biologic in Phase III development for diabetic foot ulcers

Forward Looking Statements
This website may contain forward-looking statements regarding PolarityBio’s pipeline, clinical development programs, potential future indications, regulatory strategy, and business plans. These statements are subject to risks and uncertainties, including those inherent in clinical development, regulatory review, and commercialization. Actual results may differ materially. PolarityBio undertakes no obligation to update forward-looking statements except as required by law.